NVS Phase 3 readout: a positive outcome, +1.1%

On February 26, 2026, TQJ230 — Novartis AG (Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease) reached its Phase 3 readout. The result was a positive outcome, and the stock moved +1.1% in the window around the event. It had already run +15.1% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.